Analyst Price Target is $17.50
▲ +185.02% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Compugen in the last 3 months. The average price target is $17.50, with a high forecast of $19.00 and a low forecast of $16.00. The average price target represents a 185.02% upside from the last price of $6.14.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Compugen. This Buy consensus rating has held steady for over two years.
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.